Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Operating Expenses (2018 - 2024)

X4 Pharmaceuticals' Other Operating Expenses history spans 4 years, with the latest figure at $105.0 million for Q2 2024.

  • For Q2 2024, Other Operating Expenses changed N/A year-over-year to $105.0 million; the TTM value through Mar 2025 reached $105.0 million, changed N/A, while the annual FY2024 figure was $105.0 million, N/A changed from the prior year.
  • Other Operating Expenses reached $105.0 million in Q2 2024 per XFOR's latest filing, up from -$509000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $105.0 million in Q2 2024 to a low of -$509000.0 in Q4 2022.